Phase I study of epirubicin plus docetaxel (ET) in patients (pts) with hormone refractory prostate cancer (HRPC)

4784 Background: Doxorubicin formulation with improved tolerance would increase the drug’s therapeutic ratio and enhance the efficacy. Anthracyclines demonstrates similar toxicity. Epirubicin has a...